Key facts
- It has raised $150K; the latest was Early Stage VC ($150K) in Feb 2025.
- Notable investors include Charles River Incubator Program, Dammam Valley, National Technology Development Program, Saudi Biotech, TURN8.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for NanoPalm
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoPalm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoPalm
Operator of a biotechnology company intended to create nanomedicine for pharmaceutical R&D activities. The company offers artificial intelligence (AI)-driven manufacturing of next-generation lipid nanoparticles (NG-LNPs), develops biorobots in drug discovery and a gene editing therapeutic nanorobot for patients, enabling patients with Sickle Cell Disease and other genetic diseases to get treatment while minimizing side effects.
- Sector
- Healthcare
- HQ
- Riyadh, Saudi Arabia
- Founded
- 2022
- Employees
- 12
- Website
- nanopalm.ltd/
- Ownership
- Privately Held (backing)
NanoPalm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoPalm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoPalm in its N-PORT filings yet. We sweep new filings monthly.